Drug Coated Balloon-Only Strategy in De Novo Lesions of Large Coronary Vessels.

J Interv Cardiol 2019 3;2019:6548696. Epub 2019 Feb 3.

Innere Medizin III, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Germany.

Objectives: We analyzed the efficacy of drug coated balloons (DCB) as a stand-alone-therapy in de novo lesions of large coronary arteries. DCBs seem to be an attractive alternative for the stent-free interventional treatment of de novo coronary artery disease (CAD). However, data regarding a DCB-only approach in de novo CAD are currently limited to vessels of small caliber.

Methods: By means of propensity score (PS) matching 234 individuals with de novo CAD were identified with similar demographic characteristics. This patient population was stratified in a 1:1 fashion according to a reference vessel diameter cut-off of 2.75 mm in small and large vessel disease. The primary endpoint was the rate of clinically driven target lesion revascularization (TLR) at 9 months.

Results: Patients with small vessel disease had an average reference diameter of 2.45 ± 0.23 mm, while the large vessel group averaged 3.16 ± 0.27 mm. Regarding 9-month major adverse cardiac event (MACE), 5.7% of the patients with small and 6.1% of the patients with large vessels had MACE (p=0.903). Analysis of the individual MACE components revealed a TLR rate of 3.8% in small and 1.0% in large vessels (p=0.200). Of note, no thrombotic events in the DCB treated coronary segments occurred in either group during the 9-month follow-up.

Conclusions: Our data demonstrate for the first time that DCB-only PCI of de novo lesions in large coronary arteries (>2.75 mm) is safe and as effective. Interventional treatment for CAD without permanent or temporary scaffolding, demonstrated a similar efficacy for large and small vessels.

Download full-text PDF

http://dx.doi.org/10.1155/2019/6548696DOI Listing
February 2020

Publication Analysis

Top Keywords

large coronary
lesions large
novo lesions
large vessels
large vessel
coronary arteries
interventional treatment
patients small
novo cad
vessel disease
drug coated
population stratified
coronary segments
target lesion
clinically driven

Similar Publications

Treatment of Very Small De Novo Coronary Artery Disease With 2.0 mm Drug-Coated Balloons Showed 1-Year Clinical Outcome Comparable With 2.0 mm Drug-Eluting Stents.

J Invasive Cardiol 2018 07 15;30(7):256-261. Epub 2018 Apr 15.

Department of Cardiology, National University Heart Centre, 1E Kent Ridge Road, NUHS Tower Block, Level 9, Singapore 119228.

Objective: To evaluate the 1-year clinical outcomes of patients treated with 2.0 mm drug-coated balloon (DCB) vs 2.0 mm drug-eluting stent (DES) implantation in small-caliber vessel de novo coronary artery disease (CAD). Read More

View Article and Full-Text PDF
July 2018

Treatment of large de novo coronary lesions with paclitaxel-coated balloon only: results from a Chinese institute.

Clin Res Cardiol 2019 Mar 3;108(3):234-243. Epub 2018 Aug 3.

Department of Cardiology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, China.

Background: To evaluate the efficacy of paclitaxel-coated balloons (SeQuent Please) for large de novo coronary lesions with diameters greater than 2.8 mm.

Methods: We performed a retrospective study of 527 consecutive patients with 595 de novo lesions (222 lesions) that comprised the large vessel disease (LVD) group, with a reference diameter (RD) ≥ 2. Read More

View Article and Full-Text PDF
March 2019

A propensity score matched comparative study between paclitaxel-coated balloon and everolimus-eluting stents for the treatment of small coronary vessels.

Catheter Cardiovasc Interv 2017 Sep 21;90(3):380-386. Epub 2017 Jan 21.

Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy.

Objectives: To compare the long-term clinical outcomes of paclitaxel drug-coated-balloons (DCB) and everolimus-eluting-stents (EES) following the treatment of de novo small vessel coronary artery disease.

Background: It is currently unclear whether treatment of de novo small vessel coronary disease with DCB is comparable to second generation drug-eluting stents, which are the current standard of care.

Methods: The present study enrolled 90 patients with small vessel coronary disease from the DCB treatment arm of the BELLO (Balloon Elution and Late Loss Optimization) trial and 2,000 patients treated with EES at the San Raffaele Scientific Institute. Read More

View Article and Full-Text PDF
September 2017

12-Month clinical results of drug-coated balloons for de novo coronary lesion in vessels exceeding 3.0 mm.

Int J Cardiovasc Imaging 2019 Apr 30;35(4):579-586. Epub 2019 Mar 30.

Department of Cardiology, Xijing Hospital, Fourth Military Medical University, No. 15 Changle West Road, Xi'an, 710032, China.

The purpose of this observational study was to investigate the feasibility, initial safety, and efficacy of the SeQuent® Please DCB (B. Braun Melsungen, Germany) for patients with de novo coronary lesions in vessels exceeding 3.0 mm in a consecutive series of all comer percutaneous coronary intervention. Read More

View Article and Full-Text PDF
April 2019